Genomic Landscape of Mixed-Phenotype Acute Leukemia

Marah Hennawi, Nagehan Pakasticali, Hammad Tashkandi and Mohammad Hussaini *

Department of Pathology and Laboratory Medicine, Moffitt Cancer Center, Tampa, FL 33612, USA
* Correspondence: mohammad.hussaini@moffitt.org; Tel.: +1-813-745-6118

Abstract: Mixed-phenotype leukemia (MPAL) is a type of acute leukemia in which the blast population shows mixed features of myeloid, T-lymphoid, and/or B-lymphoid differentiation. MPALs are rare and carry a poor prognosis, thus, often pose both a diagnostic and therapeutic challenge. Conventionally, the diagnosis of MPAL requires either a single blast population with a lineage-defining phenotypic expression of multiple lineages (myeloid, B-cell and/or T-cell) (biphenotypic) or two distinct blast populations that each independently satisfy criteria for designation as AML, B-ALL, and/or T-ALL (bilineage). Given the rarity of MPAL, minimal studies have been performed to describe the genomic landscape of these neoplasms. IRB approval was obtained. Central MCC database was searched for any patient with a diagnosis of acute undifferentiated leukemia (AUL), acute leukemia of ambiguous lineage (ALAL), and MPAL. All patient diagnoses were manually reviewed by a hematopathologist to confirm the diagnosis of MPAL. Genomic and molecular data were collated from the EMR and bioinformatically from MCC genomics repositories. Twenty-eight patients with MPAL were identified. Thirteen were female and 15 were male. Average age was 56 years old (range = 28–81). Ten cases were biclonal and 18 were biphenotypic. Diagnoses were as follows: B/myeloid (n = 18), T/myeloid (n = 9), and T/B (n = 1). Cytogenetic analysis (Karyotype +/- FISH) was available for 27 patients. The most frequent recurrent abnormalities were complex karyotype (n = 8), BCR/ABL1 translocation (n = 6), Del 5q/-5 (n = 4), Polysomy 21 (n = 4). Mutational analysis was available for 18 patients wherein mutations were detected in 45 unique genes. The most frequently mutated genes were TP53 (7), RUNX1 (6), WT1 (4), MLL2 (3), FLT3 (3), CBL (2), ASXL1 (2), TET2 (2), MAP3K6 (2), MLL (2), and MAP3K1 (2). Targetable or potentially targetable biomarkers were found in 56% of cases. Overall survival was 19.5 months (range = 0–70 m). Ten patients were treated with an allogeneic stem cell transplant and had superior outcome (p = 0.0013). In one of the largest series of MPAL cases to date, we corroborate previous findings with enriched detection of RUNX1 and FLT3-ITD mutations along with discovery of unreported mutations (MAP3K3) that may be amenable to therapeutic manipulation. We also report the frequent occurrence of AML with MDS-related changes (AML-MRC)-defining cytogenetic abnormalities (26%). Finally, we show that those patients that received stem cell transplant had a better overall survival. Our findings support the need to genomically profile MPAL cases to exploit opportunities for targeted therapies in this orphan disease with dismal prognosis.

Keywords: mixed-phenotype acute leukemia; mutations; NGS; genomic; targeted therapy

1. Introduction

Mixed-phenotype leukemia (MPAL) is a type of acute leukemia in which the blast population(s) show mixed features of myeloid, T-lymphoid, and/or B-lymphoid lineage [1]. MPALs are rare, comprising only 2–5% of acute leukemias, and carry a poor prognosis, thus, often posing both a diagnostic and therapeutic challenge [2]. The first consensus algorithm for diagnosing MPAL was proposed by the European Group for Immunological Characterization of Acute Leukemias (EGIL) in 1995 and involved a point system based on expression of various phenotypic markers by the blasts. This classification gave way to
the World Health Organization (WHO) criteria which require either a single blast population with lineage-defining phenotypic expression of multiple lineages (myeloid, B-cell and/or T-cell) (biphenotypic) or two distinct blast populations that each independently satisfy criteria for designation as AML, B-ALL, and/or T-ALL (bilineage). In this scheme, emphasis is placed on certain lineage-defining markers, namely CD19, CD3 (cytoplasmic or surface), and myeloperoxidase for B-cell, T-cell, and myeloid lineages, respectively [3]. The new proposed International Consensus Classification (ICC) classification incorporates \textit{ZNF384} rearrangement and myeloid/lymphoid neoplasm with eosinophilia (M/LN-eo) with tyrosine kinase (TK) gene fusions which can present as B/myeloid MPAL. However, the immunophenotypic criteria for MPAL do not appear to be modified [4]. Additionally, the newest rendition (5th edition) of the WHO Classification of hematolymphoid tumors categorizes acute leukemias with \textit{ZNF384} rearrangement or \textit{BCL11B} rearrangement under acute leukemia of ambiguous lineage with defining genetic abnormalities, even if they qualify as MPAL phenotypically. The criteria for immunophenotypically defined MPAL remains largely unchanged according to the WHO criteria, although antigen expression parameters have been revised and refined [5]. Overall, given the rarity of MPAL, there are only a few studies describing the genomic landscape of these neoplasms. This is important since these primitive neoplasms have overlapping clinical, immunophenotypic, and genetic features, suggesting a biological spectrum amongst acute leukemias warranting additional genomic data to guide classification, and subsequently, patient management. In particular, genetic profiling for personalized treatment and prognosis makes additional genomic characterization necessary. In this study, we report on one of the largest cohorts of MPAL in the literature, along with their genomic and clinical characteristics.

2. Results

Twenty-eight patients with MPAL were identified. Thirteen were female and 15 were male. The average age was 56 years old (range= 28–81 years). Ten cases were biclonal and 18 were biphenotypic. Diagnoses were as follows: B/myeloid (\(n= 18\)), T/myeloid (\(n= 10\)), and T/B (\(n= 1\)).

Cytogenetic analysis (Karyotype and or FISH) was available for 27 patients (Table 1). The most frequent recurrent abnormalities were complex karyotype (8), BCR/ABL1 translocation (6), Del 5q/−5 (4), and Polysomy 21 (4). In our cohort, additional MDS-related cytogenetic abnormalities included del7/−7 (3), Trisomy 8 (1), Del 17p/−17 (2), del 20q (1), del 9q (1), and del 13q (1). No patients with \textit{ZNF384} rearrangements were found.

There were three patients with rearrangements involving 14q23, which may result in the dysregulation of \textit{BCL11B} [6]. In two patients, karyotype showed 45, XY,t(2;14;5) (q23;q32;q13), der (12;16) (q10;p10), add (17)(q21) and 46,XX,t(2;14)(p13;q32)\(c\) [20]. ISH on the lymph node of the third patient identified a karyotypically occult translocation (5;14) resulting in the TLX3–BCL11b fusion (74%). All three showed T/myeloid disease. NGS showed \textit{WT1} C265R (VAF: 49%) in the second patient and \textit{WT1} (81%) and \textit{PHF6} (40%) alterations in the third patient’s lymph node. NGS was not performed on the first patient.

For those who were BCR/ABL1-positive (6), three were p210-positive and two were p190-positive, and one patient was positive for both p210 and p190.

Four patients had TP53 mutations, two of which had complex karyotype.

Other rearrangements included t(1;16) (q12;q11.2), which has been previously described in B-lymphoid blast crisis of chronic myeloid leukemia. Other novel translocations in MPAL included t(1;3) (q21;p25). An identical translocation involving \textit{BCL9} has been previously reported in Burkitt lymphoma [7]. Finally, the canonical t(8;14)(q24;q32) of Burkitt lymphoma was detected in one case. This is the first report of this translocation in MPAL. The patient had a history of HIV and hepatitis C and presented diplopia, B symptoms, abdominal pain and CSF involvement. He expired within a week of presentation. Cytogenetic data are summarized in Table 1 and Figure 1.
Table 1. Summary of karyotypic and fluorescence in situ hybridization (FISH) findings.

| Diagnosis | Clonality     | Cytogenetics                                                                 | FISH                                                                 |
|-----------|---------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|
| B/myeloid | Biclonal      | 47,XX,+6 [3]/46,XX [17]                                                      | BCR/ABL1-negative, MDS FISH-negative.                                  |
| T/B lymphoid | Biphenotypic | 65, XY, +X, +1, 1, add(1)(p33)x2, – 2, +3, – 4, +5, del(5q31)x35)x2, +6, +7, +8, – 9, +11, +20, +20, – 20, +21, +22, +mar [1]/46, XY [2] | Monosomy 16/16q, No rearrangement of CBFB, MLL, BCR/ABL, RUNX1/T/RUNX1, or PML/RARA. |
| T/myeloid | Biphenotypic  | 45,XY,t(2;14;5)(q23;q32)x13, der (12;16) (q10;p11), add (17)(q21)            | FISH-negative.                                                         |
| B/myeloid | Biphenotypic  | 47,XX/46,XX                                                             | Normal for MLL, 5q and 7q.                                             |
| T/myeloid | Biphenotypic  | 45,XY,add(X)(p22.1),–5,add(6)(q13),–7,add(9)(p11),del(9)(q13)x22, +21, +mar [6]/46,XX [17] | No evidence of a BCR-ABL rearrangement.                                |
| T/myeloid | Biphenotypic  | 46,XX,t(2;14)(p13;q32)x1/20                                               | PML/RARx rearrangement is not detected.                                |
| B/myeloid | Biclonal      | t(9;22)(q34;q11.2);46, XY, der(16)t(1;16)(q12)x1;19;46, XY [1]              | t(9;22) along with loss of CBFB/16q, and gain in RUNX1/21q.           |
| T/myeloid | Biphenotypic  | 46,XX,add(X)(p22.1),−5,add(6)(q13),−7,add(9)(p11),del(9)(q13)x22, +21, +mar [6]/46,XX [17] | No evidence of a BCR/ABL1 gene rearrangement; deletion of 5q, 7q, 17q, and 20q not detected. Monosomy 7 and trisomy 8 not detected. |
| B/myeloid | Biclonal      | 46,XX;92,idem x2 [2]                                                      | A total of 5.5% of cells with tetrasomy 8 and tetrasomy 21. No evidence of RUNX1/T/RUNX1, MLL gene rearrangement. The 4 MLL probe fusion signals (13.5%) indicate the presence of tetraploidy tumor clone in the specimen. Normal CDKN2A/P16, ETV6/RUNX1, TCF3; t(9;22)(q34;q11.2)(Normal). |
| T/myeloid | Biphenotypic  | 46,XX,t(2;17;8)(p23;q25;q22),t(9;22)(q34;q11.2),del(13)(q22)x32, +21 [cp20] | No evidence of a BCR/ABL1 gene rearrangement; deletion of 7q or monosomy 7 not detected. |
| B/myeloid | Biclonal      | 46,XX [20]                                                                   | Positive for deletion of 7q or monosomy 7 (89%).                       |
| T/myeloid | Biphenotypic  | 46,XY,–7,t(9;22) (q34;q11.2) [15]/46,XY [5]                                 | No BCR/ABL1.                                                          |
| B/myeloid | Biclonal      | 93–108,XXYY,–2,–3,–6,–6,–7,–8,–9,add(11)(q23)x2,–12,–12,+15,+10-25mar[cp3]/46,XY [19]; POSSIBLE KMT2A (MLL) Oncogene Mediated Clone Detected | No BCR–ABL1, MLL or RUNX1/RUNX1 rearrangements. Increased ABL1 and BCR signals, evidence of MLL gene amplification and increased RUNX1, RUNX1T1 signals. |
| T/myeloid | Biphenotypic  | 46,XX [20]                                                                   | Positive for del(17p/TP53), loss of ABL1 and BCL-6 genes, gain of BCR gene, and negative for BCR/ABL1 fusion, t(11;14), or BCL-2/BCL-6/MYC rearrangements. Negative for PML–RARA, RUNX1–RUNX1T1, CBFB–MYH11, BCR–ABL1, and MLL/KMT2A translocations. MDS FISH panel is normal. Deletion 5q31-negative, deletion 7q31-positive, deletion 20q12-positive, deletion 17p13 (p53)-negative, Trisomy 8-positive. |
| B/myeloid | Biclonal      | 46,XX [20]                                                                   | No RUNX1/T1, RUNX1 (ETO/AML1), MLL GENE, BCR/ABL1-negative; Del 5q31 detected at relapse. |
| T/myeloid | Biphenotypic  | 46,XX,del(5)(q22;q35),del(11)(p11.2) with an abnormal BCR–ABL1 signal with only one ABL1 gene at 9q34 detected; First relapse: 46,XX,add(1)(p36.3),del(5)(q22),+6,del(11)(p11.2),+19[cp17]/46,XX [3] | FISH negative for BCR/ABL1; no AML OR ALL gene deletions or rearrangements. |
Table 1. Cont.

| Diagnosis   | Clonality   | Cytogenetics                                                                 | FISH                                                                                           |
|-------------|-------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| B/myeloid   | Biphenotypic| 45,XX,der(3)(1;3)(q21;p25), t(8;14)(q24;q32), der(14)(8;14), −15, del(17)(p11.2), add(19)(q13.4)[cp20] | MLL deletion (63%); no BCR–ABL1 fusion.                                                        |
| B/myeloid   | Biclonal    | 46,XY [20]                                                                   | No t(8;21), t(9;22), 11q23, t(15;17) or inv16.                                               |
| T/myeloid   | Biphenotypic| 46,XY,dup(1)(q23q32), del(3)(q21), +13, −21[cp10]/46,XY[4]                   | MDS FISH panel is normal; no t(9;22) translocation.                                           |
| T/myeloid   | Biclonal    | 46,XY [20]                                                                   | No PML/RARA gene rearrangement.                                                               |
| T/myeloid   | Biclonal    | 46, XX                                                                       | Karyotypically occult translocation (5;14) resulting in the TLX3–BCL11b fusion (74%) with 60% heterozygous/hemizygous deletion of CDKN2a and with 8.5% of nuclei demonstrating a TRB rearrangement involving 7q34. |
| B/myeloid   | Biclonal    | 46,XX,add(5)(q11.2),t(9;22)(q34.1;q11.2)[18]/47,idem,+der(22)t(9;22)[1]/46,XX[1] | Positive for t(9;22), and negative for t(1;19), MYC, KMT2A or IGH gene rearrangements, negative for Trisomy 4, 6, 10 or 17. |
There were three patients with rearrangements involving 14q23, which may result in the dysregulation of BCL11B [6]. In two patients, karyotype showed 45, XY, t(2;14;5)(q23;q32;q13), der (12;16) (q10;p10), add (17)(q21) and 46,XX,t(2;14)(p13;q32)?c [20]. ISH on the lymph node of the third patient identified a karyotypically occult translocation (5;14) resulting in the TLX3–BCL11 b fusion (74%). All three showed T/myeloid disease. NGS showed WT1 C265R (VAF: 49%) in the second patient and WT1 (81%) and PHF6 (40%) alterations in the third patient’s lymph node. NGS was not performed on the first patient.

For those who were BCR/ABL1-positive (6), three were p210-positive and two were p190-positive, and one patient was positive for both p210 and p190.

Four patients had TP53 mutations, two of which had complex karyotype.

Other rearrangements included t(1;16) (q12 ;q11.2), which has been previously described in B-lymphoid blast crisis of chronic myeloid leukemia. Other novel translocations in MPAL included t(1;3) (q21;p25). An identical translocation involving BCL9 has been previously reported in Burkitt lymphoma [7]. Finally, the canonical t(8;14)(q24;q32) of Burkitt lymphoma was detected in one case. This is the first report of this translocation in MPAL. The patient had a history of HIV and hepatitis C and presented diplopia, B symptoms, abdominal pain and CSF involvement. He expired within a week of presentation. Cytogenetic data are summarized in Table 1 and Figure 1.

Mutational analysis was available for 18 patients wherein mutations were detected in 45 unique genes. The most frequently mutated genes were TP53 (7), RUNX1 (6), WT1 (4), MLL2 (3), FLT3 (3), CBL (2), ASXL1 (2), TET2 (2), MAP3K6 (2), MLL (2), and MAP3K1 (2) (Figures 1 and 2). Mutational data are summarized in Figures 2 and 3.

Figure 1. Frequency of common cytogenetic alterations in mixed-phenotype acute leukemia (MPAL).

Figure 2. Mutation frequency in mixed-phenotype acute leukemia (MPAL).
| Patient | NTRK1 | MYST3 | XRPA | BRCA2 | BRIP1 | FANCD2 | WHSC1 | FIM | CIC | ACTB | BRK1 | B31 | FLI1 | TKD | SETBP1 | IDH2 | SRSF2 | RAD21 | CBL | RUNX1 | WT1 | DNMT3A | ASXL1 | SF3B1 | TET12 | MAP3K6 | TFF3 | MIL | PHF6 | BCORL1 | MAP3K1 | JAK3 | STAT4 | ERBB2 | RELN | ASMTL | CRP24 | TLL2 | MIL2 | PRKDC | TCF3 | FLCN | SPEN |
|---------|-------|-------|------|-------|-------|--------|-------|-----|-----|------|------|-----|------|-----|---------|-----|-------|-------|-----|-------|-----|---------|-------|-------|-------|-------|-------|------|-------|-------|-------|-------|-------|------|-------|-------|
| 1       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 2       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 3       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 4       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 5       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 6       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 7       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 8       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 9       |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 10      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 11      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 12      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 13      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 14      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 15      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 16      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 17      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |
| 18      |       |       |      |       |       |        |       |     |     |      |      |     |      |     |          |     |       |       |     |       |     |         |       |       |       |       |       |     |       |       |       |       |     |       |       |       |       |     |       |       |

**Figure 3. Cont.**
There was considerable heterogeneity in treatment. Most patients received ALL therapy with most receiving Hyper-CVAD, or modifications thereof (B/myeloid = 12; T/myeloid = 2). Some patients received myeloid therapy such as hypomethylating agent (HMA) (T/myeloid = 1, B/myeloid = 1 (+Venatoclax)) or 7 + 3 (B/myeloid = 3, T/myeloid = 2). Relapses were treated with Midastaurin, HMA, CLAG-M, Sorefenib, or Venetoclax + HMA.

A subset of patients were found to have targetable mutations. Of the three patients with FLT3-ITD mutations, one (B/Myeloid) was treated with adjuvant Midastaurin initially and adjuvant Gilteritinib at relapse, with a response. The other patient (T/myeloid) received adjuvant Sorefanib with HyperCVAD for reinduction upon relapse and achieved complete remission, but later relapsed. The last patient was diagnosed with MPAL prior to the release of FLT3-targeted therapy. One patient with targetable IDH2 R140Q was detected but he expired in 14 days. We also note the recurrent involvement ($n = 3$) of the MAPKKK family of serine/threonine-specific kinases involved in proliferation and differentiation, which warrants an additional investigation as a target. Lastly, the KMT2 (MLL) family was also noted to be recurrently involved ($n = 3$), raising the possibility of targeting with anti-KMT2A (KO-539), of which is in trial.

Overall survival was 19.5 months (range= 0–70). Ten patients were treated with an allogeneic stem cell transplant. Mean survival for those with transplant was 34.1 months (SD 21.5) versus 11.4 months (SD 11.9) for those without ($p = 0.0013$).

3. Discussion

Early studies reporting on MPAL either lacked mutational data, only looked at limited genes, or involved the analysis of one to two patients [8–11]. A notable exception is what is still one of the largest series of MPAL ($n = 117$) to date, with diseases classified based on the 2008 WHO criteria. In that study, cytogenetic data were available for 92 patients; in order of frequency, they showed complex karyotype (24%), BCR/ABL1 fusion (15%), −7 (8%), Polysomy 21 (8%), and t(v;11q23) (4%). They performed a mutational analysis on 31 patients for 17 genes and found mutations in 12 patients—the most common being: IKZF1 deletions (13%), EZH2 (9.7%), and ASXL1 (6.5%). No mutations in DNMT3A, FBXW7, FLT3, IDH1, IDH2, KIT, NPM1, PHF6, RUNX1, or WT1 were reported [12].
Subsequently a large multicenter US-based study identified nine cases of B/T MPAL, where recurrent mutations in PHF6 and the involvement of JAK-STAT and Ras signaling pathways were reported [13].

In a more recent study by Takahashi et al., an integrated genomic analysis was performed on 31 MPAL samples. Abnormal karyotype was found in nearly 70% of cases. Overall, 26% had complex karyotype abnormalities, 13% were Philadelphia chromosome (Ph+)-positive, and one case had a 11q23 rearrangement (t [11;19][q23;p13.3]). They examined 295 genes in all 31 patients and found mutations in 94% of cases. The most common mutations were found in NOTCH1 (29%), RUNX1 (26%), and DNMT3A and IDH2 (23% each) [14]. B/myeloid cases were enriched for RUNX1 mutations. In our data set, this was confirmed, as RUNX1 mutations were seen exclusively with the B/myeloid phenotype.

Limited studies have investigated pediatric acute leukemia of ambiguous lineage (ALAL). A large multicenter, international study looked at 110 cases of MPAL and found 81 recurrently mutated genes to include FLT3 (27%), RUNX1 (13%), CDKN2A or CDKN2B (19%), ETV6 (20%), VPREB1 (13%), WT1 (24%), and KMT2A (23%) [15]. However, genes involved in adult MPAL (e.g., IDH2, DNMT3A) appeared to be absent in the pediatric MPAL [16]. These data are summarized in Table 2.

In our study, we confirm many of the previous findings but expand on the data in significant ways. In one of the largest series of adult MPAL cases with cytogenetic and mutational results, first we found the frequent occurrence of AML-MRC-defining cytogenetics abnormalities (n = 7, 26%) and MDS-defining chromosomal abnormalities (n = 12; 44%), even after excluding cases with complex karyotype. There is ambiguity in the 2016 WHO classification with regard to how to categorize these cases. On the one hand, it has been suggested that cases of AML with MDS-related changes (AML-MRC) should be designated as such with a note regarding mixed-phenotype of blasts. However, MDS-defining cytogenetic abnormalities are also listed in the genetic profile of neoplasms categorized as B/myeloid MPAL by 2008 WHO. To address this conundrum, we examined the clinical behavior of these groups by comparing the OS of MPAL patients with and without AML-MRC-defining cytogenetic abnormalities. Those who harbored these abnormalities had a lower overall survival (11.14 months) versus those that did not (22.95 months) (p = 0.1697). Larger cohort studies will be needed to further refine diagnostic criteria and confirm these findings.

Next, we looked at those patients with an exceptionally poor prognosis (OS less than 4 months; n = 8). Blast percentage was high at diagnosis (86%). They were B/myeloid (6), T/myeloid (1) and T/B (1). One half had complex karyotype. No particular set of mutations was enriched in this group. Treatment strategies were heterogenous like the overall group, with the exception that only one of these patients received a transplant.

Next, we reported a different set and distribution of genetic alterations consistent with long-tail distribution of mutations in lymphomas [17]. Forty-five unique genes were found to be mutated, more than reported in prior studies. The most frequently mutated genes included were TP53 (7), RUNX1 (6), and WT1 (4). In addition, we found a substantial subset of patients with targetable or potentially targetable disease (56% of those who were profiled). Three patients had FLT3–ITD, two of whom received TKI therapy with a response. Another patient had IDH2 R140Q, which would have been amenable to enasidenib therapy had the patient survived [18]. Three patients had aberrations of the KMT2 family, thus, providing a basis for an investigation on anti-KMT2A therapy. KO-539 is currently in clinical trial (NCT04067336) and preliminary data have shown anti-leukemic activity in patient-derived xenograft (PDX) models [19]. Uniquely, we discovered a recurrent involvement (n = 3) of the MAPKK family in serine/threonine-specific kinases, of which are involved in cellular proliferation and differentiation. Several FDA-approved therapies already target MAPK signaling, such as BRAF and MEK inhibitors, and their use in MPAL patients with alterations in this pathway is worthy of further investigation.
| Table 2. Summary of prior genomic studies of MPAL. |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                 | Heesch, S. et al. [8] | Eckstein, O.S. et al. [9] | Quesada, A.E. et al. [10] | Matutes, E. et al. [11] | Yan, L. et al. [12] | Mi, X. et al. [13] | Takahashi, K. et al. [14] | Alexander, T.B. et al. [15] | Becker, M. et al. [16] |
| **Sex**                        | Female          | Male           | Female          | Male           | Female          | Male           | Female          | Male           | Female          | Male           |
| **Age, years**                 | Median          | Median         | Median          | Median         | Median          | Median         | Median          | Median         | Median          | Median         |
| **Diagnosis**                  |                |                |                |                |                |                |                |                |                |                |
| AUL                            | 16             | 21             | 13             | 26             | 13             | 26             | 13             | 26             | 13             | 26             |
| ALL                            | 2              | 2              | 2              | 2              | 2              | 2              | 2              | 2              | 2              | 2              |
| AML                            | 38             | 62             | 39             | 51             | 39             | 51             | 39             | 51             | 39             | 51             |
| MPAL (B/Myeloid)               | 12             | 7              | 7              | 9              | 7              | 9              | 7              | 9              | 7              | 9              |
| MPAL (T/Myeloid)               | 12             | 15             | 6              | 35             | 38             | 18             | 49             | 52             | 49             | 52             |
| MPAL (B/T-cell)                | 2              | 1              | 1              | 4              | 1              | 4              | 1              | 4              | 1              | 4              |
| MPAL (B/T/Myeloid)             |                |                |                |                |                |                |                |                |                |                |
| **Cytogenetics**               |                |                |                |                |                |                |                |                |                |                |
| Normal karyotype               | 3              | 4              | 10             | 33             | 5              |                |                |                |                |                |
| Complex karyotype              |                |                |                |                |                |                |                |                |                |                |
| t(9;22)(q34;q11)               | 7              | 1              | 1              | 15             | 14             | 4              | 2              |                |                |                |
| Monosomy                       | 5              |                |                |                |                |                |                |                |                |                |
| Polysomy                       |                |                |                |                |                |                |                |                |                |                |
| t(10;11)(p15;q21)              |                |                |                |                |                |                |                |                |                |                |
| MLL                            | 2              |                |                |                |                |                |                |                |                |                |
| Other abnormalities            | 11             |                |                |                |                |                |                |                |                |                |
| **Mutations**                  |                |                |                |                |                |                |                |                |                |                |
| WT1                            | 4              | 3              | 3              | 0              | 1              | 28             | 24             |                |                |                |
| FLT3                           | 1              | 3              | 3              | 0              | 1              | 28             | 24             |                |                |                |
| DNMT3A                         | 6              |                | 6              | 1              | 0              | 7              |                |                |                |                |
| MLL                            | 2              |                | 2              | 2              | 8              | 1              | 8              | 15             | 13             |                |
| NOTCH1                         | 5              |                | 5              |                |                |                |                |                |                |                |
| NRAS                           | 4              |                | 4              |                |                |                |                |                |                |                |


Twenty patients achieved complete remission (CR), while seven patients demonstrated persistent disease. The overall survival in the group with persistent disease was dismal (2.9 months). In the CR group, the mutational profile included TP53 (4), RUNX1 (3), and FLT3 (2). Cytogenetics showed del 5q (2), complex (3), and t(9;22) (2) in this group.

Finally, we confirm the dismal prognosis of patients with MPAL diagnosis (19.5 months). We note a wide variance in treatment strategies but show that hematopoietic stem cell transplantation is an effective treatment for these patients. The mean survival for those with a transplant was significantly superior at 34.1 months (SD 21.5) versus 11.4 months (SD 11.9) for those without a transplant ($p = 0.0013$).

4. Materials and Methods

IRB approval was obtained. The Central Moffitt Cancer Center (MCC) database was searched for any patients with a diagnosis of acute undifferentiated leukemia (AUL), acute leukemia of ambiguous lineage (ALAL), or mixed-phenotype acute leukemia (MPAL) from a database of >600,000 entries. All patient diagnoses were manually reviewed by a board-certified hematopathologist to confirm the diagnosis based on the 2016 WHO classification. Cases with myeloid component and complex karyotype were classified as MPAL and were included in the cohort. Genomic and molecular data were collated from the electronic medical record and bioinformatically from MCC genomics repositories. Next generation sequencing data were derived from either Foundation One Heme® Testing or in-house CAP/CLIA-certified Illumina-based myeloid NGS panels, or 98-gene myeloid (Sophia-based custom Myeloid Action Panel) NGS panels performed on these patients.

FoundationOne Heme (Foundation Medicine, Cambridge, Massachusetts) is a combined DNA- and RNA-sequencing assay that uses hybrid-capture NGS technology to detect single nucleotide base substitutions, insertions and deletions, copy number variants, and certain fusions across >400 protein-coding genes, 250 RNA transcripts, and 30 selected introns that are potentially involved in hematologic malignancies. Sensitivity, specificity, and reproducibility were reported to be greater than 95% [20,21].

NGS was performed at the Moffitt Cancer Center in a CAP/CLIA-certified environment using a custom TruSeq myeloid 32-gene panel that was transitioned to an Illumina TruSight Myeloid 54-gene panel in 2016 [22]. Insertions/deletions were reported at a validated variant allele frequency (VAF) of >10%. Single nucleotide variants were reported with a variant allele frequency (VAF) of ≥ 5% in all tests.

The Moffitt-MAP assay is based on a customized NGS assay from SOPHiA Genetics and Illumina sequencing technology platform. For library generation, a hybridization-capture-based enrichment method was employed; Illumina sequencing by synthesis (SBS®) technology was used to interrogate the following genes: ABL1, ANKRD26, ASXL1, ASXL2, ATM, ATRX, BCO1, BCO2L1, BRAF, BRC3, CALR, CBL, CBLB, CCND2, CDKN2A, CEBPA, CHEK2, CREBBP, CSF3R, CSM1, CSNK1A1, CTCF, CX31, DDX41, DHX15, DNMT3A, ELANE, ETV1, ETV6, EZH2, FANC, FANCl, FLT3, GATA1, GATA2, GNAS, GNB1, HNRNPA, HRAS, IDH1, IDH2, IKZF1, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KMT2D, KRAS, LUCP2, MECOM, MET, MPL, MYC, NF1, NOTCH1, NOTCH2, NPM1, NRAS, PAX5, PDGFRα, PHF5, PIGA, PML, PPM1D, PTPN11, RAD21, RAFl, RBI, RBPP6, RPS19, REL1, RUNXI, SAMD9, SAMD9L, SBDS, SETBP1, SF3B1, SH2B3, SMCI, SMC3, SOS1, SRP7, SRSF2, STAG1, STAG2, STAT3, STAT5B, TERC, TERT, TET2, TP53, U2AF1, WT1, ZBTB7A, ZRSR2. Insertions/deletions, as well as single nucleotide variants, were reported at a variant allele frequency cut-off >3%.

5. Conclusions

In summary, our findings expand on the molecular underpinnings of MPAL and may carry prognostic implications in a disease subset with already a dismal prognosis. In one of the largest series of MPAL cases to date, we corroborate previous findings with an enriched detection of RUNX1 mutations, along with the discovery of unreported mutations (MAP3K) that may be amenable to therapeutic manipulation. Our findings support the
need to genomically profile MPAL cases to exploit opportunities for targeted therapies in this orphan disease with dismal prognosis. In addition, we note the frequent occurrence of AML-MRC-related cytogenetic abnormalities in MPAL patients which seem to carry a worse prognosis and may qualify for their own designation as a disease category; however, larger corroborative studies are needed. Lastly, we provide evidence for stem cell transplants as an effective treatment strategy for patients with this aggressive disease.

**Author Contributions:** Data curation, M.H. (Marah Hennawi) and M.H. (Mohammad Hussaini); Formal analysis, M.H. (Marah Hennawi) and M.H. (Mohammad Hussaini); Investigation, M.H. (Mohammad Hussaini); Methodology, M.H. (Mohammad Hussaini); Supervision, H.T. and M.H. (Mohammad Hussaini); Writing—original draft, Marah Hennawi; Writing—review & editing, N.P., H.T. and M.H. (Mohammad Hussaini). All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board and Scientific Review Committee of Moffitt Cancer Center (Approval Code: MCC 17964 and Pro00032696 Approval Date: 12 December 2018).

**Informed Consent Statement:** Patient consent was waived due to the retrospective nature of this study and the exemption granted by the IRB.

**Data Availability Statement:** Data will be made available upon reasonable request to the corresponding author.

**Conflicts of Interest:** MOH: Consulting Fees (Adaptive Biotechnology, Stemline, Amgen, Boston Biomedical, Decibio, Tegus, Bristol Myers Squibb, Wells Fargo), Honoraria (Adaptive Biotechnology, Stemline, Amgen, Boston Biomedical, Bristol Myers Squibb, Blueprint Medicine).

**References**

1. Wolach, O.; Stone, R.M. How I treat mixed-phenotype acute leukemia. *Blood* 2015, 125, 2477–2485. [CrossRef] [PubMed]
2. Weinberg, O.K.; Arber, D.A. Mixed-phenotype acute leukemia: Historical overview and a new definition. *Leukemia* 2010, 24, 1844–1851. [CrossRef] [PubMed]
3. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016, 127, 2391–2405. Erratum in *Blood* 2016, 128, 462–463. [CrossRef] [PubMed]
4. Arber, D.A.; Orazi, A.; Hasserjian, R.P.; Borowitz, M.J.; Calvo, K.R.; Kvasnicka, H.M.; Wang, S.A.; Bagg, A.; Barbui, T.; Branford, S.; et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. *Blood* 2022, 140, 1200–1228. [CrossRef]
5. Khoury, J.D.; Solary, E.; Abla, O.; Akkari, Y.; Alaggio, R.; Apperley, J.F.; Bejar, R.; Berti, E.; Busque, L.; Chan, J.K.C.; et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* 2022, 36, 1703–1719. [CrossRef]
6. Di Giacomo, D.; la Starza, R.; Gorello, P.; Pellanera, F.; Atak, Z.K.; de Keersmaecker, K.; Pierini, V.; Harrison, C.J.; Arniani, S.; Moretti, M.; et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. *Blood* 2021, 138, 773–784.
7. Willis, T.G.; Zalcberg, I.R.; Coignet, L.J.A.; Wlodarska, I.; Stul, M.; Jadayel, D.M.; Bastard, C.; Treleaven, J.G.; Catovsky, D.; Silva, M.L.M.; et al. Molecular Cloning of Translocation t(1;14)(q21;q32) Defines a Novel Gene (BCL9) at Chromosome 1q21. *Blood* 1998, 91, 1873–1881. [CrossRef]
8. Heesch, S.; Neumann, M.; Schwartz, S.; Bartram, I.; Schlee, C.; Burmeister, T.; Hänel, M.; Ganser, A.; Heuser, M.; Wendtner, C.-M.; et al. Acute leukemias of ambiguous lineage in adults: Molecular and clinical characterization. *Ann. Hematol.* 2013, 92, 747–758. [CrossRef]
9. Eckstein, O.S.; Wang, L.; Punia, J.N.; Kornblau, S.M.; Andreeff, M.; Wheeler, D.A.; Goodell, M.A.; Rau, R.E. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. *Exp. Hematol.* 2016, 44, 740–744. [CrossRef]
10. Quesada, A.E.; Hu, Z.; Routbort, M.J.; Patel, K.P.; Luthra, R.; Loghavi, S.; Zuo, Z.; Yin, C.C.; Kanagal-Shamanna, R.; Wang, S.A.; et al. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. *Oncotarget* 2018, 9, 8441–8449. [CrossRef]
11. Matthew, E.; Pickl, W.F.; Veer, M.V.; Morilla, R.; Swansbury, J.; Strobl, H.; Attarbaschi, A.; Hopfinger, G.; Ashley, S.; Bene, M.C.; et al. Mixed-phenotype acute leukemia: Clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood* 2011, 117, 3163–3171. [CrossRef] [PubMed]
12. Yan, L.; Ping, N.; Zhu, M.; Sun, A.; Xue, Y.; Ruan, C.; Drexler, H.G.; MacLeod, R.A.F.; Wu, D.; Chen, S. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. *Haematologica* 2012, 97, 1708–1712. [CrossRef] [PubMed]

13. Mi, X.; Griffin, G.; Lee, W.; Patel, S.; Ohgami, R.; Ok, C.Y.; Wang, S.; Geyer, J.T.; Xiao, W.; Roshal, M.; et al. Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. *Am. J. Hematol.* 2018, 93, 1358–1367. [CrossRef] [PubMed]

14. Takahashi, K.; Wang, F.; Morita, K.; Yan, Y.; Hu, P.; Zhao, P.; Zhar, A.A.; Wu, C.J.; Gumbs, C.; Little, L.; et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. *Nat. Commun.* 2018, 9, 2670. [CrossRef] [PubMed]

15. Alexander, T.B.; Gu, Z.; Iacobucci, I.; Dickerson, K.; Choi, J.K.; Xu, B.; Payne-Turner, D.; Yoshihara, H.; Loh, M.L.; Horan, J.; et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature* 2018, 562, 373–379. [CrossRef] [PubMed]

16. Becker, M.W.; O'Dwyer, K.M. Comprehensive Genomic Classification of Pediatric Mixed-Phenotype Acute Leukemia. *Hematologist* 2019, 16. [CrossRef]

17. Zhang, J.; Grubor, V.; Love, C.L.; Banerjee, A.; Richards, K.L.; Mieczkowski, P.A.; Dunphy, C.; Choi, W.; Au, W.Y.; Srivastava, G.; et al. Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 2013, 110, 1398–1403. [CrossRef] [PubMed]

18. Abou Dalle, I.; Dinardo, C.D. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. *Ther. Adv. Hematol.* 2018, 9, 163–173. [CrossRef] [PubMed]

19. Davis, J.A.; Fiskus, W.C.; Daver, N.; Mill, C.P.; Birdwell, C.; Salazar, A.; Philip, K.; Kadia, T.M.; Dinardo, C.D.; Leoni, M.; et al. Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models. *Blood* 2021, 138 (Supp. S1), 3357. [CrossRef]

20. Roloff, G.W.; Baron, J.J.; Neppalli, V.T.; Sait, S.; Griffiths, E.A. Next-Generation Sequencing Delineates Clonal Origins and Informs Therapeutic Strategies in Acute Lymphoblastic Leukemia and Histiocytic Sarcoma. *JCO Precis. Oncol.* 2019, 3, 1–8. [CrossRef] [PubMed]

21. Frampton, G.M.; Fichtenholtz, A.; A Otto, G.; Wang, K.; Downing, S.R.; He, J.; Schnall-Levin, M.; White, J.; Sanford, E.; An, P.; et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat. Biotechnol.* 2013, 31, 1023–1031. [CrossRef] [PubMed]

22. Au, C.H.; Wa, A.; Ho, D.N.; Chan, T.L.; Ma, E.S.K. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. *Diagn. Pathol.* 2016, 11, 11. [CrossRef] [PubMed]